What about the acquisition of a marketing and distribution company?
In an interview following the third Phase 2 result, the topic of acquisition was raised by the interviewer. I think it’s in the context of additions to the drug pipeline, but why not bolt on a sales and marketing division and retain all the value of NNZ-2591?
Timestamp: 23:30
On the Couch with Jon Pilcher: What’s Next for Neuren Pharma
A search on Grok suggests there are a few options that could be "affordable" (less than $1B). With successful Phase 3 approvals, we should be worth US$7–10B, so it could be a good investment.
Ann: Update - Notification of buy-back - NEU, page-50
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |